Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mechanical ventilation using high oxygen tensions is often necessary to treat patients with respiratory failure. Recently, TLRs were identified as regulators of noninfectious oxidative lung injury.
IRAK-M
is an inhibitor of MyD88-dependent TLR signaling. Exposure of mice deficient in
IRAK-M
(
IRAK-M
(-/-)) to 95% oxygen resulted in reduced mortality compared with wild-type mice and occurred in association with decreased alveolar permeability and cell death. Using a bone marrow chimera model, we determined that
IRAK-M
's effects were mediated by structural cells rather than bone marrow-derived cells. We confirmed the expression of
IRAK-M
in alveolar epithelial cells (AECs) and showed that
hyperoxia
can induce the expression of this protein. In addition,
IRAK-M
(-/-) AECs exposed to
hyperoxia
experienced a decrease in cell death.
IRAK-M
may potentiate hyperoxic injury by suppression of key antioxidant pathways, because lungs and AECs isolated from
IRAK-M
(-/-) mice have increased expression/activity of heme oxygenase-1, a phase II antioxidant, and NF (erythroid-derived)-related factor-2, a transcription factor that initiates antioxidant generation. Treatment of
IRAK-M
(-/-) mice in vivo and
IRAK-M
(-/-) AECs in vitro with the heme oxygenase-1 inhibitor, tin protoporphyrin, substantially decreased survival and significantly reduced the number of live cells after
hyperoxia
exposure. Collectively, our data suggest that
IRAK-M
inhibits the induction of antioxidants essential for protecting the lungs against cell death, resulting in enhanced susceptibility to hyperoxic lung injury.
...
PMID:TLR signaling prevents hyperoxia-induced lung injury by protecting the alveolar epithelium from oxidant-mediated death. 2266 Oct 86